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Abstract
Background: Cryptococcal infections, besides being a problem for immunocompromised patients, are occasionally
being a problem for immunocompetent patients. In addition, the lower susceptibility of this yeast to azoles is a
growing problem in health care. To date, there are very few molecules with any activity towards Cryptococcus
neoformans, leading to heightened interest in finding new alternatives or adjuvants to conventional drugs for the
treatment of mycosis caused by this yeast. Since the essential oils (EOs) are considered as a potential rich source of
bioactive antimicrobial compounds, we evaluated the antifungal activity of Origanum vulgare (oregano), Pinus
sylvestris (pine), and Thymus vulgaris (thyme red) EOs, and their components (α-pinene, carvacrol, thymol) compared
with fluconazole, itraconazole, and voriconazole, against C.neoformans clinical strains. Then, we investigated the
effect of EOs and components in combination with itraconazole.
Methods: EO composition was analysed by Gas chromatography-mass spectrometry (GC-MS). A broth microdilution
method was used to evaluate the susceptibility of C.neoformans to azoles, EOs and components. Checkerboard tests,
isobolograms and time-kill assays were carried out for combination studies.
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Results: Six C.neoformans isolates were susceptible to azoles, while one C.neoformans exhibited a reduced susceptibility to
all tested azole drugs. All EOs exerted a good inhibitory activity against all C.neoformans strains. Pine EO was the most
effective. Among components, thymol exerted the most remarkable activity. By checkerboard testing and isobolographic
analysis, combinations of itraconazole with oregano, pine, or thyme EOs, and carvacrol were found to be synergistic
(FICI≤0.5) against azole susceptible C.neoformans. Regarding the azole not susceptible C.neoformans strain, the synergistic
effect with itraconazole was observed with thyme EO (chemotype: thymol 26.52%; carvacrol 7.85%), and carvacrol. Time-kill
assays confirmed the synergistic effects of itraconazole and oregano or thyme EO against azole susceptible C.neoformans.
Binary mixtures of itraconazole/thyme EO or carvacrol yielded additive effects on the azole not susceptible C.neoformans.
Conclusions: Our findings highlight the potential effectiveness of thyme, oregano EOs, and carvacrol as natural
and cost-effective adjuvants when used in combination with itraconazole. Identification of EOs exerting these
effects could be one of the feasible ways to overcome drug resistance, reducing drug concentration and side effects.
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Background
Systemic fungal infections caused by Cryptococcus neo-
formans, an encapsulated pathogenic yeast, are a serious
health concern for immunocompromised patients world-
wide, and occasionally in immunocompetent subjects [1, 2].
Cryptococcal infection occurs by inhalation of dried yeast
cells from avian excreta, especially from Columba livia
pigeons, causing potentially severe pulmonary infection,
followed by haematogenous spread to the central nervous
system, with meningoencephalitis being the predominant
clinical presentation in human HIV-infected patients [1].
The currently recommended therapy for cryptococcosis is
amphotericin B (AMB), due to its high fungicidal activity
in the central nervous system, usually in combination
with 5-flucytosine. However, long-term treatment with
AMB has certain drawbacks due to toxic side effects (i.e.
nephrotoxicity and hepatotoxicity). In addition to AMB
formulations, low-dose fluconazole (FLC) and itraconazole
(ITC) are used as long-term maintenance therapy of
cryptococcosis, whereas voriconazole (VRC) and posa-
conazole (POS) are used as consolidation therapy. Com-
pared to other azoles, ITC has a lower toxicity, and a
better therapeutic index, which allow using this drug even
for organ transplant, and AIDS patients [3]. Despite the
effectiveness of these drugs, many recent studies indicate
that the widespread use of azoles, mainly FLC, is associ-
ated with the emergence of drug-resistant isolates, and re-
lated treatment failures and infection relapses, during
long-time or repeated treatment [4]. To date, there are
few other molecules with any activity towards C.neofor-
mans, leading to heightened interest in finding new alter-
natives to conventional drugs for the treatment of mycosis
caused by this yeast [1]. Particularly, essential oils (EOs)
have emerged in recent years as potential natural and
economic alternatives or as adjuvants in combination
with conventional antifungal agents and continue to be
of great interest [5–10]. A large number of EOs and
their major components have shown to exhibit a wide
range of biological properties (antibacterial, antifungal,
antiviral, anti-inflammatory, anticancer) [11–16]. More-
over, as EOs are multicomponent, there is a low prob-
ability by microorganisms to develop resistance to this
mixture of substances than to a single target.
Notably, Pinus sylvestris L. (Pinaceae), Origanum vul-
gare L. (Lamiaceae), and Thymus vulgaris L. (Lamiaceae)
EOs, as well as their main components (α-pinene, carva-
crol, and thymol) have long been known for their wide use
in phytomedicine, thanks to their numerous beneficial
properties, including antibacterial and antifungal activities
[16, 17]. A smaller number of comprehensive studies have
focused on interaction of these EOs and their major
components with available antifungal drugs against C.
neoformans [18]. Conversely, these EOs and main com-
ponents have been widely investigated against a wide
range of bacteria [19, 20], yeasts, especially Candida
spp. [12, 13, 21], moulds [15], but to a lesser extent on
C.neoformans [22, 23].
In this study, we evaluated the antifungal activity of P.
sylvestris (pine), O.vulgare (oregano), and T.vulgaris
(thyme red) EOs, and their main components (α-pinene,
carvacrol, and thymol), in comparison with that exerted
by FLC, ITC and VRC against C.neoformans clinical isolates
from HIV-infected patients with cryptococcosis. Then, we
investigated the effect of EOs and EO components in
combination with ITC against C.neoformans isolates.
Unlike FLC, ITC is a very lipophilic drug, which may
enhance penetration into the yeast cell, allowing its use
also in combination with other high lipophilic compounds,
such as EOs.
Methods
Essential oils and main components
Commercial EOs of P.sylvestris L., Pinaceae (pine), and
T.vulgaris L., Lamiaceae – thymol chemotype (thyme red)
were purchased from Azienda Agricola Aboca (Sansepolcro,
Arezzo, Italy) as steam distilled samples. O. vulgare L.,
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Lamiaceae (oregano) EO was obtained by hydrodistilla-
tion and kindly provided by Herboris Orientis Dacor
(Milan, Italy). EO main components (positive enantio-
mer (+) of α-pinene, carvacrol, and thymol: ≥98% pur-
ity) were purchased from Sigma-Aldrich (Milan, Italy)
and used as received without any further purification.
All samples were protected from light and humidity
and stored at 4 °C until use.
GC-MS analysis
All reference standards used for GC analysis were of
chromatographic grade and were purchased from Sigma-
Aldrich (Milan, Italy). Chromatographic grade organic sol-
vents were from Sigma-Aldrich (Milan, Italy). Analyses
were performed on a 7890A gas chromatograph (Agilent
Technologies, Waldbronn, Germany), coupled with a
5975C Network mass spectrometer (Agilent Technologies).
The compounds were separated on an HP-5 MS cross-
linked poly-5% diphenyl-95% dimethyl polysiloxane
(30 m × 0.25 mm i.d., 1.00 mm film thickness) capil-
lary column (Agilent Technologies). The column was
initially 45 °C, then increased to 100 °C at a rate of 2 °C/
min then it was raised to 250 °C at a rate of 5 °C/min and
finally it was held for 5 min. The injection volume was
0.1 μl, with a split ratio 1:50. Helium was used as the
carrier gas at a flow rate of 0.7 ml/min. The injector
temperature was set at 250 °C. MS detection was per-
formed with electron ionization (EI) at 70 eV, operating
in the full-scan acquisition mode in the m/z range 40–
400. EOs were diluted 1:20 (v/v) with n-hexane before
GC-MS analysis [5].
GC-FID analysis
Analyses were carried out on a 7820 gas chromatograph
(Agilent Technologies), with flame ionization detector (FID).
The compounds were separated on a HP-5 cross-
linked poly-5% diphenyl-95% dimethyl polysiloxane
(25 m × 0.2 mm i.d., 0.25 mm film thickness) capillary
column (Agilent Technologies). The injection volume
and the temperature program were the same as de-
scribed above. The split ratio was 1:20. Helium was
used at a flow rate of 1 ml/min. The injector and de-
tector temperatures were set at 250 °C and 300 °C, re-
spectively. EOs and reference standards were diluted
1:20 (v/v) with n-hexane before GC-FID analysis [5].
Qualitative and quantitative analysis
The compounds were identified by the comparison of
their linear retention indices (LRI) relative to C8-C40
n-alkanes (Sigma-Aldrich, Milan-Italy) under the above-
mentioned conditions with those provided in the literature
[24]. Furthermore, the identification of the several constit-
uents was carried out by the comparison of their mass
spectra with those recorded in the National Institute of
Standards and Technology (NIST version 2.0d, 2005)
and, when necessary, identification was carried out by
co-injection of available reference compounds. The rela-
tive percentage amounts of individual components were
expressed as the percentage peak area relative to the total
composition of the EO obtained by the GC-FID analysis.
Quantitative data were acquired as the mean of triplicate
analyses for each sample.
Essential oils and their components stock solutions
Stock solutions of each EO and its components were
prepared in ethanol (1:2.5) and diluted (1:20) to obtain a
final concentration of 2% (v/v) in RPMI-1640 medium
without sodium bicarbonate and with L-glutamine (Sigma-
Aldrich), buffered to pH 7.0 with 0.165 M morpholinepropa-
nesulfonic acid (MOPS) (Sigma-Aldrich) and supplemented
with 0.2% glucose [15]. Tween 80 (Sigma-Aldrich) (final con-
centration 0.001%, v/v) was used to enhance EO solubility,
with no inhibitory effect on yeast growth.
Antifungal drugs
FLC, ITC, and VRC powders (≥ 98% purity by HPLC)
were purchased from Sigma-Aldrich (n° F8929, I6657, and
PZ0005, respectively). FLC stock solutions were made up in
sterile distilled water, while ITC and VRC stock solutions
were made up in 100% dimethylsulfoxide (Sigma-Aldrich),
and stored at − 20 °C until use.
Yeast isolates
Seven C. neoformans sensu lato clinical isolates from
HIV-infected patients with cryptococcosis, admitted to
Amedeo di Savoia Hospital (Turin, Italy) between Janu-
ary 2013 and December 2014, were tested. Yeast isolates
were identified by the API ID32C identification systems
(BioMérieux, Rome, Italy). Then, they were stored at −
80 °C in Microbanks™ (Pro-Lab Diagnostics, Neston, UK),
and sub-cultured at least twice on Sabouraud dextrose
agar (SDA, Oxoid, Milan, Italy) at 35 °C for 72 h before
testing.
Inoculum preparation
A starting inoculum of yeast cells was prepared by inocu-
lating three or four colonies grown on SDA agar plates in
sterile saline and adjusting the yeast suspension to a 0.5
McFarland turbidity standard, corresponding to ≈ 5 × 106
cells/ml. The starting inoculum was diluted in RPMI 1640
(Sigma-Aldrich) broth medium to yield a final inoculum
of 0.5–2.5 × 103 colony forming unit/ml (CFU/ml). The
inoculum size was checked by plating serial dilutions on
SDA and determining the colony counts in triplicate after
incubation at 35 °C for up to 72 h [12].
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Antifungal susceptibility testing
C. neoformans isolates were tested for in vitro susceptibil-
ity to FLC, ITC, and VRC by broth microdilution (BM)
method, according to Clinical and Laboratory Standards
Institute (CLSI) M27-A3 (2008) [25]. As guidelines are
not available for EO susceptibility testing, the antifungal
activity of EOs and EO major components was assessed
following the CLSI BM assay, with some modifications
[12, 15]. Minimum inhibitory concentration (MIC) de-
termination was performed in RPMI-1640 medium with
L-glutamine without sodium bicarbonate (0.2% glucose)
(Sigma-Aldrich), buffered to pH 7.0 with 0.165 M
MOPS (Sigma-Aldrich), using 96-well microtiter plates
(Sarstedt, Milan, Italy).
A volume of 100 μl of the inoculum suspension was
transferred into microtiter plates containing 100 μl of
two-fold serial dilutions of FLC (range 0.06–128 μg/ml),
ITC (range 0.0078–2 μg/ml), VRC (range 0.0078–32 μg/ml),
EOs (range 0.07–10 mg/ml) and EO components (range
0.02–10 mg/ml), respectively. RPMI 1640 medium alone
was used as growth control. The microtiter plates were in-
cubated at 35 °C for 72 h. MICs of azoles were read as the
lowest drug concentration that produced ≥50% growth
inhibition compared to the growth control. EO and EO
component MICs were read as the lowest concentra-
tion at which no yeast growth was observed.
Minimum fungicidal concentrations (MFCs) were de-
termined by spot inoculating 10 μl from wells containing
either azoles or EO/EO component concentrations with
inhibition of yeast growth onto SDA plates, which were
incubated at 35 °C for 72 h. MFC was defined as the low-
est concentration resulting in no growth on subculture,
and corresponding in the death of 99.9% or more of the
initial inoculum [15]. Due to the lack of clinical break-
points, the recently published epidemiological cutoff
values (ECVs) were used in defining C. neoformans re-
sistance profile to FLC (ECV, 16 μg/ml), ITC (ECV,
1 μg/ml), and VRC (ECV, 0.25 μg/ml), respectively [26].
Checkerboard assays and assessment of FIC index
Combinatorial effects between ITC and EOs/EO main
components were evaluated by the checkerboard broth
microdilution assay. Based on the antifungal susceptibility
testing results, one azole susceptible (ADS 37) and one
not-susceptible (ADS 006) C.neoformans isolates were
selected to assess drug synergism. Therefore, a two-
dimensional checkerboard with serial twofold dilutions
of each compound, ranging from several dilutions below
the MIC to 2 ×MIC, was set up. Binary combinations
were mixed within a 96-well microtiter plate. Then, yeast
cell suspensions were prepared to yield final inoculum
of ~ 1.5 × 103 CFU/ml, and were added to each well
containing binary mixtures of either ITC/EOs or ITC/EO
main compounds. Each strain was tested in duplicate.
Plates were incubated by shaking (150 rpm) at 35 °C for
72 h, and, afterwards, they were read visually.
The results were analysed using the fractional inhibitory
concentration index (FICI). FICI values were determined
by considering all first clear well in each row of the micro-
plate containing combinations of ITC and EO/EO main
components with no visible yeast growth. FICI was calcu-
lated as follows: FICI=FICa+FICb =MICa in combination/
MICa tested alone+MICb in combination/MICb tested
alone; where MICa and MICb are the MICs of ITC and of
each tested EO used alone against C. neoformans, respect-
ively. Synergy and antagonism were defined by FICI values
of ≤0.5 and > 4, respectively. A FICI value between 0.5 and
1.0 was considered as additive, while a value between
1.0 and 4.0 was considered as indifferent [27].
Isobolograms
Results of the checkerboard assays were represented
graphically by isobolograms. Corresponding FIC values
along the growth-no growth interface were calculated
and reported by plotting FIC values of ITC along the or-
dinate, and FIC values of EOs/EO components along the
abscissa. The straight line that joins the intercept points,
corresponding to combined effects equal to the sum of the
individual compounds, is the line of additivity (FICI = 1).
Below this line we find the area of additive (0.5 < FICI< 1)
and synergistic (FICI≤0.5) effects, respectively. FIC
index values above of the straight line were interpreted
as indifferent (1 < FICI< 4) or antagonistic (FICI> 4) in-
teractions [27].
Time-kill studies
Time–kill assays were performed with binary synergistic
mixtures of either ITC/EOs or ITC/EO main components
according to the results of the checkerboard assays
against C. neoformans ADS 37 and C. neoformans ADS
006 strains. To examine the rate of killing of each com-
bination, oregano, pine and thyme red EOs, and carva-
crol were tested either alone or in combination with
ITC at sub-MIC levels. For each tested strain, yeast cell
suspension was prepared in sterile saline solution (0.85%
NaCl) and turbidity was adjusted with 0.5 McFarland stand-
ard (approximately 106 CFU/ml). Then, yeast suspension
was diluted in RPMI medium to yield a final inoculum
concentration of ~ 5 × 103 CFU/ml. Test tubes containing
binary combinations or compounds alone, were inoculated
with the yeast suspension. Untreated yeast cells were used
as growth control. For each strain tested, assays were
performed in duplicate.
At predetermined time points (0, 2, 6, 24, 48 and 72 h)
of incubation by shaking (150 rpm) at 35 °C, aliquots of
500 μl were removed and serially ten-fold diluted in
sterile water for colony counting. A 100 μl sample from
each dilution was spread onto SDA plates. After 72 h
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incubation at 35 °C the mean number of CFU/ml was
determined, and viable counts were plotted against time
on a log10 scale. Reduction in viable counts ≥2 log10
after 72 h incubation in comparison with the cell count
of the most active single substance was interpreted as
synergy. Additivity was defined as a 1–2 log10 decrease
in viable counts, whereas antagonism was defined as
a > 1 log10 increase in viable counts [27].
Statistical analysis
All experiments were performed in duplicate and repeated
at least twice. The time-kill data were analysed with
one-way ANOVA followed by Bonferroni test (Graph-
PadPrism7, San Diego, CA, USA). The threshold for
statistical significance was set at a p value of < 0.05.
Results
Composition of the EOs
The phytochemical composition of oregano, pine and
thyme red EOs used for this study was determined by
GC-MS and results were reported in Table 1. Pine EO was
found to be rich in α-pinene (55.76%) with lower percent-
ages of β-pinene (9.034%) and of limonene (9.74%). In
thyme red EO the two major components were thymol
Table 1 Chemical composition of tested essential oils as determined by GC-MS analysis
Number Componenta LRIb Origanum vulgare % Pinus sylvestris % Thymus vulgaris %
1 α-Thujene 926 0.34 0.02 0.27
2 α-Pinene 933 0.95 55.76 11.50
3 Camphene 947 0.17 1.79 1.10
4 Sabinene 973 – 0.13 –
5 β-Pinene 979 0.60 9.034 0.77
6 β-Myrcene 992 2.34 3.41 1.30
7 α-Phellandrene 1004 0.17 0.19 0.10
8 δ-3-Carene 1009 – 6.96 1.30
9 α-Terpinene 1017 1.08 0.47 0.49
10 p-Cymene 1025 12.36 2.01 16.26
11 Limonene 1029 0.54 9.74 13.20
12 1,8-Cineole 1033 – – 1.29
13 trans-Ocimene 1048 – 0.03 0.03
14 γ –Terpinene 1059 7.60 0.10 4.02
15 Terpinolene 1088 – 0.81 0.40
16 cis-Sabinene hydrate 1098 – 0.06 0.13
17 trans-Pinocarveol 1140 – 0.12 –
18 Camphor 1144 – 0.07 1.37
19 Borneol 1166 – 0.12 0.69
20 Terpinen-4-ol 1179 0.86 0.21 0.63
21 p-Cymen-8-ol 1186 – 0.25 0.04
22 α-Terpineol 1192 – 0.87 1.22
23 Verbenone 1210 – 0.07 –
24 Bornyl-acetate 1289 – 0.95 –
25 Thymol 1295 5.12 – 26.52
26 Carvacrol 1305 62.61 – 7.85
27 α-Cububene 1355 – 0.11 –
28 α-Copaene 1381 – 0.14 –
29 β-Caryophyllene 1425 0.89 0.94 1.34
30 α-Humulene 1460 – 0.11 –
31 γ –Muurolene 1481 – 0.06 –
32 Caryophyllene oxide 1593 1.01 – –
aCompounds are listed in order of elution
bLinear retention index (LRI) calculated on HP-5 column
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and its precursor p-cymene (26.52%, and 16.26%, respect-
ively), followed by a high content of limonene (13.20%),
α-pinene (11.50%), carvacrol (7.85%), and γ-terpinene
(4.02%). Oregano EO was found to be rich in carvacrol
(62.61%), its precursor p-cymene (12.36%), and in γ-ter-
pinene (7.60%) (Table 1). Particularly, the phytochemical
composition of oregano EO proved to be highly rich in
phenolic monoterpenes, in accordance with data reported
in European Pharmacopoeia 9th Ed., and only minor differ-
ences were observed [28].
Antifungal susceptibility testing
Based on susceptibility testing results, six C. neoformans
isolates were found to be susceptible to FLC (MIC range =
0.25–4 μg/ml), ITC (MIC range = 0.25–0.5 μg/ml), and
VRC (MIC range = 0.015–0.125 μg/ml), while one C. neo-
formans was found to exhibit a reduced susceptibility to all
tested azole drugs, as MIC values were above the reference
ECVs (Table 2). Amongst EOs, pine EO exhibited a high
inhibitory activity on the growth of all C. neoformans azole
susceptible isolates, with low MIC values ranging from
0.07 to 0.27 mg/ml (Table 2). As reported in Table 2,
oregano and thyme red EOs were fairly effective in inhibit-
ing C. neoformans growth, displaying MICs ranging from
0.3 to 0.6 and from 0.56 to 1.12 mg/ml, respectively. Fi-
nally, all EOs displayed a good antifungal activity against
the C. neoformans isolate with low susceptibility to azoles,
and the rank order of the most effective EOs decreased as
follows: oregano>pine>thyme EO (Table 2).
Among main components, thymol was found to be the
most active pure compound, displaying the lowest MIC
values (range 0.02–0.08 mg/ml) towards all C. neoformans
isolates, irrespective of their susceptibility profile to azoles.
Likewise, carvacrol and α-pinene were found to be
particularly effective in inhibiting the growth of all C.
neoformans isolates (Table 2). Conversely, terpinen-4-ol
displayed moderate antifungal activity, whereas γ-terpinene
exhibited weak activity against C. neoformans (data not
shown). Furthermore, MFC results were generally equiva-
lent or one more concentration above the MICs, indicat-
ing that the selected EOs and main components were
mainly fungicidal (Table 2).
Checkerboard assays, assessment of FIC index and
isobolograms
The best combinations (i.e. those giving the lowest FICI
values) of oregano, pine and thyme red EOs and their
major components with ITC, against azole-susceptible
and not-susceptible C. neoformans isolates were evaluated
and reported in Table 3. Besides, the association profile
was also exploited from all the FIC values obtained along
the growth no-growth interface of each combination
(Figs. 1, 2). According to the FIC indexes reported for
the azole-susceptible strain, a predominantly synergistic
profile (FICI≤0.5) was detected, with a consequent de-
crease of the MICs. In addition, the isobologram profiles
were concave, confirming the presence of synergistic asso-
ciations between ITC and pine, oregano, thyme EOs as
well as between ITC and carvacrol (Fig. 1). Notably, when
synergy was not observed, no antagonism was reported
for any of the combinations. In fact, binary combinations
of ITC/α-pinene and ITC/thymol resulted in either addi-
tive (FICI = 0.625) or indifferent (FICI = 2) interactions
(Table 3), as also clearly depicted by the corresponding
isobologram plots reported in Fig. 1.
Conversely, as regards the C. neoformans displaying
low susceptibility to azoles, the synergistic effect with
ITC was only obtained with binary mixtures of ITC with
our thyme EO chemotype (thymol 26.52%; carvacrol 7.
85%), and carvacrol, respectively (FICI = 0.375, Table 3).
Oregano EO and α-pinene were found to exert additive
effects (FICI = 0.625) when used in combination with ITC,
whereas pine EO and thymol displayed indifferent interac-
tions (FICI = 1.125) in association with ITC (Table 3). The
Table 2 In vitro antifungal activity of azoles and essential oils against Cryptococcus neoformans azole-susceptible and not-susceptible
clinical isolates
Yeast strains Antifungal drugs (μg/ml) Essential oils and main components (mg/ml)
MIC/MFC MIC/MFC
FLC VRC ITC Origanum vulgare Pinus sylvestris Thymus vulgaris (+)-α-pinene Carvacrol Thymol
ADS 16 0.25/4 0.015/0.06 0.5/0.5 0.3/0.3 0.27/0.54 0.56/1.12 1.07/1.07 0.6/1.2 0.02/0.04
ADS 37 0.25/4 0.06/0.25 0.5/0.5 0.3/0.6 0.14/0.14 0.56/0.56 0.54/0.54 0.6/1.2 0.04/0.04
ADS 48 0.5/8 0.015/0.06 0.25/0.5 0.3/0.3 0.14/0.14 0.56/0.56 0.54/0.54 0.6/0.6 0.04/0.08
ADS 57 4/32 0.125/0.5 0.5/0.5 0.3/0.3 0.07/0.14 1.12/1.12 0.54/0.54 0.6/1.2 0.04/0.04
ADS 108 0.25/4 0.015/0.06 0.25/0.5 0.6/0.6 0.07/0.07 0.56/1.12 0.54/0.54 0.6/0.6 0.04/0.04
ADS 109 4/32 0.015/0.06 0.25/0.5 0.6/0.6 0.14/0.27 1.12/1.12 0.54/1.07 0.6/1.2 0.04/0.08
ADS 006 > 128/> 128 > 32/> 32 2/> 2 0.3/1.2 0.54/1.1 1.12/2.24 1.07/1.07 0.6/0.6 0.08/0.16
FLC: fluconazole; VRC: voriconazole; ITC: itraconazole
Epidemiological cut-off values (ECVs) for each antifungal drug: FLC, 16 μg/ml; VRC, 0.25 μg/ml; ITC, 1 μg/ml [26]
Scalas et al. BMC Complementary and Alternative Medicine  (2018) 18:143 Page 6 of 13
isobolographic analysis of FIC values confirmed the syner-
gistic effects of ITC/thyme EO and ITC/carvacrol binary
mixtures against the azole not-susceptible C. neoformans
strain, as in both cases the plotted isobologram points
move towards the origin of the axes (Fig. 2).
Time-kill studies
The death kinetics of synergistic mixtures were also
investigated in time kill studies and results were re-
ported in Figs. 3, 4 and 5. ITC at sub-MIC concentra-
tion (1/4 MIC) in combination with oregano and
thyme red EOs (1/8 MIC) was found to be highly ef-
fective against C. neoformans azole susceptible strain,
since a 2.84 log10 decrease in viable counts in com-
parison to ITC alone was detected after a 72 h time
lapse (Fig. 3). Time-kill results with binary combina-
tions of ITC (1/8 MIC) plus pine EO (1/4 MIC) and
ITC (1/8 MIC) plus carvacrol (1/8 MIC) yielded a de-
crease of 1.53 and 1.70 log10 in CFU/ml in compari-
son to ITC alone, displaying additive effects towards
C. neoformans ADS 37 isolate (Fig. 4). Likewise, syn-
ergistic binary mixtures of ITC (1/8 MIC) with thyme
red EO (1/4 MIC) and carvacrol (1/4 MIC) produced
additive effects (0.92 and 1.3 log10 decrease in CFU/ml)
on azole not-susceptible C. neoformans strain by time-kill
assay (Fig. 5).
Table 3 Fractional inhibitory concentration index (FICI) of essential oils plus itraconazole
Antifungal agents C. neoformans ADS 37 (azole susceptible strain) C. neoformans ADS 006 (azole not-susceptible strain)
ITC MIC (μg/ml) alone 0.5 2
Origanum vulgare MIC (mg/ml) alone 0.3 0.3
FIC of oregano oil 0.125 0.5
FIC of ITC 0.25 0.125
FICI 0.375 0.625
Interpretation SYN ADD
Pinus sylvestris MIC (mg/ml) alone 0.14 0.54
FIC of pine oil 0.25 1
FIC of ITC 0.125 0.125
FICI 0.375 1.125
Interpretation SYN IND
Thymus vulgaris MIC (mg/ml) alone 0.56 1.12
FIC of thyme red oil 0.125 0.25
FIC of ITC 0.25 0.125
FICI 0.375 0.375
Interpretation SYN SYN
(+)-α-pinene MIC (mg/ml) alone 0.54 1.07
FIC of α-pinene 0.125 0.5
FIC of ITC 0.5 0.125
FICI 0.625 0.625
Interpretation ADD ADD
Carvacrol MIC (mg/ml) alone 0.6 0.6
FIC of carvacrol 0.125 0.25
FIC of ITC 0.125 0.125
FICI 0.25 0.375
Interpretation SYN SYN
Thymol MIC (mg/ml) alone 0.04 0.08
FIC of thymol 1 1
FIC of ITC 1 0.125
FICI 2 1.125
Interpretation IND IND
FIC of ITC =MIC of ITC in combination with EO/MIC of ITC alone. FIC of EO =MIC of EO in combination with ITC/MIC of EO alone
FICI (FIC Index) = FIC of ITC + FIC of EO. IND: indifferent; ADD: additive; SYN: synergy
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Discussion
Over the last decade, cryptococcosis has increased and
has become one of the major fungal diseases of medical
importance in both immunocompromised and immuno-
competent individuals. Unfortunately, treatment failures,
due to the emergence of yeast strains resistant to azole
drugs, and mortality remain high [1]. Currently, EOs are
considered as a potential rich source of bioactive anti-
microbial compounds to improve antifungal treatment.
Moreover, synergy research is actively studying efficacy
of EOs and their main components in combination with
already existing drugs, so that drug dosages and treatment-
related adverse side effects can be significantly reduced,
preventing or delaying the development of drug resistant
strains [6–10, 18]. To date, few studies have evaluated the
combinatorial effects of EOs with azoles against C. neofor-
mans using in vitro synergy [18]. Therefore, in the present
study we tested three EOs from Lamiaceae (O. vulgare and
T. vulgaris) and Pinaceae (P. sylvestris) plant families, some
of the best inhibitors of fungal pathogens, and single main
components (α-pinene, carvacrol and thymol), against C.
neoformans clinical strains from HIV-infected patients with
cryptococcosis with a different pattern of susceptibility to
azoles (FLC, ITC, and VRC). Moreover, we evaluated
whether these natural compounds may enhance the activ-
ity of ITC against azole susceptible and not-susceptible C.
neoformans isolates.
Based on antifungal susceptibility testing, pine EO
displayed the highest inhibitory activity (MIC = 0.07–
0.27 mg/ml) on six C. neoformans isolates susceptible
to azole drugs (FLC, ITC, and VRC), whereas oregano
EO was found to be the most effective against the
azole not-susceptible isolate (MIC = 0.3 mg/ml; Table 2).
As previously seen with C. albicans by Khan et al. [21],
high antifungal activities of oregano and thyme EOs may
be ascribed to the presence of phenolic components such
as carvacrol and thymol, which may determine membrane
deterioration through oxidative stress and alteration of the
Fig. 1 Isobologram plots of ITC and EOs/EO main components against C.neoformans ADS 37 (azole-susceptible strain). Points along the isobolograms
represent the growth no-growth interface: fractional inhibitory concentration (FIC) values of ITC are plotted on x-axis, and FIC values of EOs/EO main
components are plotted on y-axis
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Fig. 3 Time-kill curve of ITC, oregano and thyme red EOs alone and in combination against C.neoformans ADS 37 (azole-susceptible strain)
Fig. 2 Isobologram plots of ITC and EOs/EO main components against C.neoformans ADS 006 (azole not-susceptible strain). Points along the
isobolograms represent the growth no-growth interface: fractional inhibitory concentration (FIC) values of ITC are plotted on x-axis, and FIC
values of EOs/EO main components are plotted on y-axis
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antioxidant defence system even at low concentrations.
Interestingly, other authors reported that thyme EO may
induce phenotypic switching on the polysaccharide cap-
sule of C. neoformans, decreasing capsule size and leading
to alteration of yeast virulence [29].
According to our MIC/MFC results, thymol, the main
component of thyme red EO, was the most effective pure
compound, exhibiting yeast growth inhibition stronger
than thyme EO alone against all C. neoformans isolates at
low MIC values ranging from 0.02 to 0.08 mg/ml (Table 2).
Thymol was also more effective than carvacrol and α-
pinene, the main bioactive components of oregano and pine
EOs, respectively. In fact, α-pinene and carvacrol showed a
good antifungal activity against all C. neoformans isolates,
though at higher MIC concentrations (Table 2). These find-
ings on α-pinene are consistent with previous studies and
may be related to significant inhibition of C. neoformans
phospholipase and esterase activities caused by both α- and
ß positive enantiomers of pinene [30]. On the contrary,
MIC results of carvacrol and thymol differ to some extent
from those previously reported by other authors [22, 23, 31,
32]. However, we would like to highlight that the methodo-
logical approaches for MIC determination used in these
studies were clearly different, rather not standard, and there-
fore susceptibility results were difficult to compare.
This study showed, for the first time, synergistic and
additive effects of combinations of pine, oregano, and
thyme red EOs with ITC against both azole susceptible
and not-susceptible C. neoformans clinical isolates. Ac-
cording to FICI results and isobolographic analysis, pine,
oregano, and thyme red EOs in combination with ITC
showed a synergistic action against azole susceptible yeast
Fig. 4 Time-kill curve of ITC, pine EO and carvacrol alone and in combination against C.neoformans ADS 37 (azole-susceptible strain)
Fig. 5 Time-kill curve of ITC, thyme red EO and carvacrol alone and in combination against C.neoformans ADS 006 (azole not-susceptible strain)
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strain. Among main components, carvacrol showed a
synergistic profile when combined with ITC, while ITC/
α-pinene and ITC/thymol combinations resulted in ei-
ther additive or indifferent interactions (Table 3). In
this study binary mixtures of ITC with our thyme EO
chemotype (thymol 26.52%; carvacrol 7.85%), and carvacrol
were found to be synergistic against azole not-susceptible
C. neoformans strain. On the contrary, oregano EO and
α-pinene were found to exert additive effects when
used in combination with ITC, whereas pine EO and
thymol displayed indifferent interactions in association
with ITC. Antagonism was never observed.
Finally, the time-kill method revealed a more detailed
insight into the antifungal activities of the synergistic
combined mixtures. In agreement with checkerboard
data, ITC at sub-MIC concentration (1/4 MIC) in com-
bination with oregano and thyme red EOs (1/8 MIC)
confirmed to be highly effective against C. neoformans
azole susceptible strain (Fig. 3). Particularly, these binary
combinations produced the same antifungal effects ob-
tained when testing the singular drug at MIC level by
time-kill assay (data not shown). The synergistic combin-
ation of ITC with our tested EO chemotypes (oregano and
thyme red) might be explained by the EOs promoting the
effects of antifungal drugs, mainly on the cell wall, plasma
membrane and other membrane structures of C. neofor-
mans. In addition, EO damage on yeast cell wall and
membrane may facilitate ITC entry into the cell, probably
leading to a greater effect on ergosterol biosynthesis inhib-
ition and adding to C. neoformans membrane destruction.
Overall, this issue might also turn the fungistatic action of
ITC into a fungicidal action [7, 9].
Conversely, time-kill results with binary combinations
of ITC (1/8 MIC) plus pine EO (1/4 MIC) and ITC (1/8
MIC) plus carvacrol (1/8 MIC) were not really consistent
with those from checkerboard assays, displaying additive
effects towards C. neoformans ADS 37 isolate (Fig. 4).
Likewise, synergistic binary mixtures of ITC (1/8 MIC)
with thyme red EO (1/4 MIC) and carvacrol (1/4 MIC)
yielded additive interactions on azole not-susceptible C.
neoformans strain (Fig. 5). Despite these apparently
contradictory results between checkerboard and time-kill
assays, these differences may be ascribed to the different
methods used, as time-kill assay records a fungicidal ef-
fect, whereas the checkerboard titration reveals at least
inhibition of fungal growth [27]. According to literature data,
an indifferent effect was detected against both C. albicans
and C. neoformans strains when α- and ß- pinene positive
enantiomers of pinene were combined with AMB [30].
Moreover, other authors have found that thymol may exert
synergistic interactions with AMB, FLC and ITC towards C.
albicans, whereas it may display either synergistic or additive,
or indifferent activities when combined with AMB, ITC, and
FLC against C. neoformans strains, respectively [18].
Terpenoids/monoterpenes are the main constituents
of plant-derived EOs, frequently used in folk medicines,
pharmaceutical industry and cosmetics. Among mono-
terpenes tested in our study, both carvacrol and thymol
have been classified as GRAS (generally recognized as
safe) for human consumption at low concentrations, as
they do not exhibit systemic toxicity. Furthemore, their
use in food has been also approved by European Parlia-
ment and Council, making them a potential option for
developing anti-cryptococcal drugs [31]. In addition, α,
and β pinene are generally considered as safe at low con-
centrations and are commonly used to produce balsamic
candies and fumigations [30]. Notably, thymol is also
widely used in dental practice, and has shown to interact
positively with the GABA(A) receptor in mouse cortical
neurons [33]. Recently, some authors demonstrated
through cytotoxicity assays and keratinocyte- Cryptococcus
spp. co-culture infection models that thymol and carvacrol
were efficient in terms of human safety, suggesting that
these pure compounds can be further exploited as
cost-effective and non-toxic anti-cryptococcal drugs [31].
Nevertheless, in human organism, other monoterpenes
(e.g., pulegone, menthofuran, camphor, and limonene)
have been reported to exhibit toxic effects in various or-
gans, mostly in liver [34]. Therefore, it is always advisable
that EOs should be used carefully, as they may be toxic
and show adverse effects on humans when overdosed [35].
Conclusions
Synergistic and additive EO/azole drug combinations
may be potential strategies to counteract antifungal re-
sistance, since use of multiple compounds may disrupt
several fungal functions and thus minimize selection of
resistant fungal strains. In this context, our findings rep-
resents an original proof-of-concept, as they highlight
the potential effectiveness of oregano, thyme red EOs and
carvacrol as natural and cost-effective adjuvants, at low
doses (i.e., < 0.1 mg/ml) [31], when used in combination
with ITC for cryptococcosis treatment.
Further in-depth studies of the modes of action for
synergistic combinations, as well as in vivo preclinical
models are encouraged to predict the translational use
of these data for clinical settings.
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